|Bid||2.8100 x 1300|
|Ask||2.8600 x 2900|
|Day's Range||2.8100 - 2.8600|
|52 Week Range||1.3500 - 4.7650|
|Beta (5Y Monthly)||1.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A look at the shareholders of Agile Therapeutics, Inc. ( NASDAQ:AGRX ) can tell us which group is most powerful...
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Investors can't complain about Agile Therapeutics' (NASDAQ: AGRX) stock performance so far this year. Agile Therapeutics doesn't have an approved product on the market yet. Agile announced Q3 total operating expenses of $14.7 million, a 227% jump from the $4.5 million reported in the prior-year period.